在收到山东证监局行政监管措施仅十余日后，山东省章丘鼓风机股份有限公司（以下简称"山东章鼓"， 002598.SZ）再迎监管重拳。 2025年12月31日，山东章鼓方面披露，公司近日收到中国证监会下发的《立案告知书》，因涉嫌定期报 告财务信息披露违法违规，公司被立案调查。 对于此次立案，山东章鼓在公告中强调，公司目前各项生产经营活动正常有序开展，并称本次立案不会 对公司生产、经营和管理造成重大影响。不过，短期内接连遭遇监管追责，仍让市场对公司的合规治理 能力产生置疑。 《中国经营报》记者梳理发现，此次立案并非无迹可循。此前，山东章鼓就因关联交易审议及信息披露 违规、募集资金使用违规、公司治理不规范等问题被中国证券监督管理委员会山东监管局（以下简 称"山东证监局"）责令整改。 值得注意的是，合规风险持续发酵的同时，山东章鼓的经营业绩也尽显疲态，2023年、2024年公司归母 净利润连续两年下滑。 从"责令改正"到"立案调查" 中经记者 王登海 卢志坤 北京报道 2025年12月19日，山东章鼓公告披露，公司当日收到山东证监局出具的《关于对山东省章丘鼓风机股份 有限公司及相关责任人员采取责令改正措施的决定》（〔20 ...

(三)公司治理不规范。部分股东大会对关联事项表决时，由关联股东担任监票人;2023年年度报告内幕信 息重大进程备忘录中，登记的公司参与人员不完整，且与内幕信息知情人档案不一致。 (二)募集资金使用违规。2024年使用募集资金购买非保本理财产品;现金管理购买的4只产品未能在董事 会授权的管理期限内全额赎回;募集资金置换相关募投项目先期投入时，将募集资金到账后继续以自有 资金支付的募投项目支出一并置换;个别募投项目未从募集资金专户直接支付相关支出。 智通财经APP讯，山东章鼓(002598.SZ)公告，公司收到中国证券监督管理委员会山东监管局出具的《关 于对山东省章丘鼓风机股份有限公司及相关责任人员采取责令改正措施的决定》。决定书指出公司存在 问题： (一)关联交易审议及信息披露违规。2024年半年报关联交易、2024年年报关联交易和关联方应收应付款 项披露不准确;2020年至2024年个别关联交易达到审议标准未及时履行审议程序和信息披露义务。 ...

Core Viewpoint - Shandong Zhanggu (002598.SZ) has received a corrective action decision from the Shandong Regulatory Bureau of the China Securities Regulatory Commission, highlighting several compliance issues related to related party transactions, fundraising, and corporate governance [1] Group 1: Related Party Transactions - The company has been found to have inaccuracies in the disclosure of related party transactions in the 2024 semi-annual report and annual report, with some transactions from 2020 to 2024 meeting the criteria for review but not undergoing timely review procedures and disclosure obligations [1] Group 2: Fundraising Violations - In 2024, the company used raised funds to purchase non-principal guaranteed financial products; four cash management products were not fully redeemed within the authorized management period set by the board [1] - The company replaced expenditures of certain fundraising projects with self-owned funds after the raised funds were received, and some project expenditures were not directly paid from the dedicated fundraising account [1] Group 3: Corporate Governance Issues - In some shareholder meetings, related shareholders acted as monitors during votes on related matters, raising concerns about governance practices [1] - The memorandum of significant progress regarding insider information in the 2023 annual report contained incomplete records of company participants, which were inconsistent with the insider information knowledge person files [1]

Core Viewpoint - The article discusses the penalties imposed on Jiaying Pharmaceutical for violations related to related party transactions and information disclosure, resulting in a total fine of 4.9 million yuan and various regulatory measures [2][3][4]. Summary by Sections Regulatory Actions - Jiaying Pharmaceutical and its chairman Li Neng, along with three other key personnel, received a total fine of 4.9 million yuan from the Guangdong Securities Regulatory Bureau for failing to disclose related party transactions and not following the necessary review procedures [2][4]. - The company also received a warning and a public reprimand from the Shenzhen Stock Exchange, highlighting the severity of the violations [2][4]. Violations Details - The violations involved non-operational fund transfers between Jiaying Pharmaceutical's subsidiary and a related party, with total amounts reaching 220 million yuan, which constituted 28.83% of the company's latest audited net assets [3][4]. - The highest daily balance of funds transferred to the related party was 89.96 million yuan, accounting for 11.79% of the company's net assets [3]. Penalties Breakdown - The penalties included a warning and a fine of 1.5 million yuan for Jiaying Pharmaceutical, while chairman Li Neng was fined 1.6 million yuan, and other executives received fines ranging from 800,000 to 1 million yuan [4]. - The company has stated that it will enhance compliance awareness and ensure accurate information disclosure moving forward [4]. Previous Violations - This is not the first time Jiaying Pharmaceutical has faced penalties for information disclosure issues, as it previously received a warning in 2021 for failing to timely disclose significant matters [5].

上述行为违反了本所《股票上市规则（2024年修订）》第1.4条、第2.1.1条、第6.3.6条、第6.3.19条的规 定。公司董事长李能、总经理游永平、时任董事会秘书肖巧霞未能恪尽职守、履行忠实勤勉义务，违反 了本所《股票上市规则（2024年修订）》第1.4条、第2.1.2条、第4.3.1条、第4.3.5条的规定，对上述违 规行为负有主要责任。 具体情况如下，2024年9月至2024年12月，公司与广东共合医药有限公司（以下简称共和医药）开展中 成药交易，相关关联交易涉及金额约875.58万元，占公司最近一期经审计净资产的1.15%。公司总经理 游永平关系密切的家庭成员刘莉民时为共和医药的控股股东，共和医药系公司关联法人。上述关联交易 未按规定履行相关决策程序和信息披露义务。 近日，嘉应制药（002198）发布公告称，公司及相关人员近日收到中国中国证券监督管理委员会广东监 管局《关于对广东嘉应制药股份有限公司、李能、游永平、史俊平、肖巧霞采取出具警示函措施的决 定》（〔2025〕128号）。 ...

Core Viewpoint - Recently, Sunflower Pharmaceutical received a warning letter from the Heilongjiang Securities Regulatory Bureau due to violations related to related party transactions, which have contributed to a significant decline in the company's performance in 2024 [1][3]. Financial Performance - In the first three quarters of 2024, Sunflower Pharmaceutical's revenue decreased by 43.24% to approximately 1.684 billion yuan, while net profit fell by 105.72% to about -33.54 million yuan, and the non-recurring net profit dropped by 117.68% to around -81.39 million yuan [2]. - The third quarter alone saw a revenue decline of 14.9% to about 374 million yuan, with net profit down 214.27% to approximately -115 million yuan, marking the first quarterly loss since the company went public [2][5]. - The company's cash flow from operating activities turned negative in the third quarter, amounting to approximately -130 million yuan, after being positive in the first half of the year [4]. Business Operations - Sunflower Pharmaceutical primarily operates in the pharmaceutical manufacturing sector, focusing on traditional Chinese medicine, chemical drugs, and health products, with key revenue sources including children's medicine and liver protection products [4]. - The company has been facing significant sales declines, attributed to seasonal factors affecting respiratory products and increased costs due to fluctuations in raw material prices [5][6]. Related Party Transactions - The warning letter specifically addressed related party transactions involving a wholly-owned subsidiary and an associated entity, which were not disclosed as required, leading to administrative measures against the company and its executives [1][3]. Research and Development - R&D expenditures have been decreasing, with a 3.51% decline in 2024 to about 124 million yuan, representing 3.67% of revenue, and a 16.78% drop in the first three quarters of 2024 to approximately 66.11 million yuan [7]. - The reduction in R&D investment raises concerns about the company's ability to innovate and sustain growth, especially as it aims to achieve a sales target of 10 billion yuan by 2028 [7]. Marketing and Sales Strategy - Sunflower Pharmaceutical has historically relied on advertising for sales, with sales expenses reaching 1.366 billion yuan in 2023, accounting for about 24% of revenue [8]. - In 2024, the company implemented cost control measures, resulting in a 68.46% reduction in sales expenses to approximately 431 million yuan, which accounted for about 12.76% of revenue [8].

Core Points - Recently, Kew Flower Pharmaceutical announced that it received a warning letter from the Heilongjiang Regulatory Bureau of the China Securities Regulatory Commission and a regulatory letter from the Shenzhen Stock Exchange [1] - The regulatory letter mentioned that in 2024, Kew Flower Pharmaceutical conducted procurement business with Shanghai Haiwei Biotechnology Co., Ltd. for an amount of 32.3836 million yuan, which accounted for 0.68% of the company's most recent audited net assets [1] - Gele Rui (Wuxi) Nutrition Technology Co., Ltd. is an affiliated legal entity of the company, and Shanghai Haiwei is a wholly-owned subsidiary of Gele Rui [1] - The transaction constitutes a related party transaction, and Kew Flower Pharmaceutical failed to follow the required review procedures and information disclosure obligations [1] - The announcement pointed out that the chairman, general manager, and board secretary of Kew Flower Pharmaceutical did not fulfill their due diligence obligations and bear primary responsibility for the violations [1]

Group 1 - The core issue involves Sanqi Interactive Entertainment (三七互娱) receiving an administrative penalty notice from the China Securities Regulatory Commission (CSRC) for multiple violations related to false disclosures in annual reports from 2014 to 2020 [1] - The violations include false records of shareholder holdings, failure to disclose related party transactions, and significant omissions in financial reports for the years 2018 to 2021 [1] - The CSRC plans to impose a fine of 9 million yuan on Sanqi Interactive Entertainment and issue warnings to the responsible individuals [1] Group 2 - The gaming ETF (product code: 159869) tracking the China Animation and Gaming Index has seen a recent decline of 2.81% over the past five days, with a price-to-earnings ratio of 37.37 times and a net inflow of 75.08 million yuan [3] - The food and beverage ETF (product code: 515170) has remained stable with no change in the last five days, a price-to-earnings ratio of 20.77 times, and a net inflow of 28.03 million yuan [3] - The Sci-Tech 50 ETF (product code: 588000) has experienced a decline of 3.06% in the last five days, with a high price-to-earnings ratio of 160.95 times and a net outflow of 1.39 billion yuan [3]

Core Viewpoint - The company received a warning letter from the Heilongjiang Securities Regulatory Bureau for failing to comply with related party transaction disclosure regulations, involving a transaction amount of 32.38 million yuan, which is 0.68% of the company's latest audited net assets [1][2]. Group 1: Regulatory Actions - The Heilongjiang Securities Regulatory Bureau issued a warning letter to the company and its executives, including the chairman and general manager, for not following the required procedures for related party transactions and information disclosure [2]. - The warning letter will be recorded in the securities and futures market integrity archives [2]. Group 2: Related Party Transactions - The company engaged in a procurement transaction with Shanghai Haiwei Biotechnology Co., a wholly-owned subsidiary of its related party, Geluori (Wuxi) Nutrition Technology Co., with a transaction amount of 32.38 million yuan [1]. - The company did not fulfill the necessary review procedures and disclosure obligations for this related party transaction, violating multiple provisions of the Information Disclosure Management Measures for Listed Companies [1].

Group 1 - Baili Technology (603959) received a regulatory warning from the Shanghai Stock Exchange due to violations related to related party transactions [1] - The company made a payment of 9.54 million yuan to Guangdong Pailer Intelligent Nano Technology Co., Ltd. for project progress from February 18 to 25, 2025, which constitutes a related party transaction [2] - The amount of the related party transaction accounted for 6.85% of the company's latest audited net assets, but the company failed to follow the required review procedures and timely disclosure [2] Group 2 - Baili Technology disclosed an estimated amount of 2.79 million yuan for related party transactions for the year 2025, while the actual amount was 4.805 million yuan, indicating inaccurate disclosure [3] - The Shanghai Stock Exchange found that the company did not comply with multiple regulations of the Shanghai Stock Exchange Listing Rules regarding related party transactions [3] - The then Chairman Lei Limeng and the then Secretary of the Board Li Liangyou were held primarily responsible for the company's violations and were issued regulatory warnings [3]